Boehringer In­gel­heim taps Sino Bio­pharm as Chi­nese part­ner for its emerg­ing can­cer pipeline

As Boehringer In­gel­heim gears up for sev­er­al po­ten­tial can­cer drug launch­es over the next few years, it is team­ing up with an ex­pe­ri­enced part­ner to de­vel­op and com­mer­cial­ize those drugs in Chi­na.

The new al­liance with Sino Bio­pharm cov­ers mul­ti­ple Boehringer clin­i­cal-stage pro­grams, in­clud­ing brigi­madlin, an MDM2 in­hibitor act­ing on the p53 path­way; zonger­tinib, a small mol­e­cule HER2 ty­ro­sine ki­nase in­hibitor; and BI 764532, a DLL3/CD3 T cell en­gager.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER